# Natera, Inc. (NTRA) Stock Analysis: A Diagnostic Powerhouse with a 17.56% Potential Upside

- Link: https://www.directorstalkinterviews.com/natera-inc-ntra-stock-analysis-a-diagnostic-powerhouse-with-a-17-56-potential-upside/4121214350
- Published: 2025-09-01T10:30:00+01:00
- Author: Madison Wilson

Natera, Inc. (NTRA), a prominent player in the healthcare sector, has carved a niche
for itself in the diagnostics and research industry. Headquartered in Austin, Texas,
Natera is renowned for its molecular testing services, offering a suite of products
designed to meet various diagnostic needs worldwide. With a market cap of $23.09
billion, the company stands as a formidable entity in the U.S. healthcare landscape.

Currently trading at $168.25, Natera’s stock price has seen a steady climb within
its 52-week range of $112.90 to $177.00. While the price change remains negligible
today, the stock’s technical indicators paint an optimistic picture. The Relative
Strength Index (RSI) at 64.12 suggests that the stock is nearing overbought territory,
yet still presents room for growth. Furthermore, the MACD of 4.79, with a signal
line of 3.58, indicates a bullish trend, aligning well with the positive sentiment
surrounding the stock.

However, Natera’s valuation metrics tell a more complex story. The absence of a 
trailing P/E ratio and a negative forward P/E of -185.55 may raise eyebrows among
traditional value investors. These figures suggest that the company is currently
operating at a loss, a fact corroborated by its negative EPS of -1.92 and a return
on equity of -24.32%. Despite these challenges, the company is showing robust revenue
growth at 32.20%, a testament to its expanding market presence and innovative product
offerings.

Natera’s product spectrum is extensive, including the Panorama non-invasive prenatal
test, Horizon carrier screening, and the Signatera molecular residual disease test,
among others. These products not only cater to prenatal and oncological diagnostics
but also extend to genetic screening and transplantation assessments. Such a diversified
product line not only mitigates risks but also positions Natera as a comprehensive
solution provider in the diagnostics arena.

The company’s financial health is further supported by a substantial free cash flow
of approximately $149.53 million, providing a cushion for continued investment in
research and development. This financial flexibility is crucial as Natera continues
to innovate and expand its product offerings.

Analyst ratings provide additional insights into Natera’s market potential. With
19 buy ratings and only one sell rating, the consensus is overwhelmingly positive.
The average target price of $197.80 suggests a notable potential upside of 17.56%
from the current price, signaling investor confidence in the company’s future performance.

Strategic partnerships play a pivotal role in Natera’s growth trajectory. Collaborations
with BGI Genomics Co., Ltd. and Foundation Medicine, Inc. highlight the company’s
commitment to advancing genetic testing technologies and expanding its market reach.

As the healthcare industry continues to evolve, Natera’s innovative approach and
comprehensive product offerings position it well for future success. For investors,
the combination of robust revenue growth, strategic partnerships, and a positive
analyst outlook make Natera, Inc. a compelling consideration in the diagnostics 
sector. While the absence of profitability may deter some, the company’s potential
for significant market expansion offers promising prospects for those willing to
embrace a growth-oriented investment strategy.

Share on:
